MGMT promoter methylation and survival following chemotherapy for WHO grade 4 IDH-mutant astrocytoma

Affiliations

• ¹ Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
• ² Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
• ³ Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
• ⁴ Inserm U1127, CNRS UMR 7225, Institut du Cerveau, ICM, Charles Foix, Service de Neuro-oncologie, Sorbonne Université, AP-HP, Hôpitaux Universitaires la Pitié Salpêtrière, Paris, France.
• ⁵ Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ⁶ Molecular Diagnostics Laboratory, Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.